Ipsen CFO: 'We Need To Stay Focused' So Didn't Bid For Onivyde ex-US Rights
Executive Summary
Ipsen let French peer Servier buy Shire's oncology assets, including rights for Onivyde in Europe, to concentrate on its coming Cabometyx EU launch and ongoing launch of Onivyde in the US.